

North Central Cancer Treatment Group

N0392: Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials

Addendum 2– November 16, 2007

Summary

Administrative/Editorial changes

Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.

Title page Reflects the addition of Addendum 2.

Protocol Resources page

Page 2 Barbara Warren’s title has been revised to reflect the currently used title as follows:

Barbara A. Warren
NCCTG *Research Base* ~~Protocol Administration~~ **Data Management**
Specialist

Section 4.0 **Study Design**

Page 8 The fourth paragraph has been revised as follows because this study is only open to treatment trials and the reference to “cancer control” was inadvertently left in the protocol:

Questionnaire booklets will be added to the NCCTG Phase II/III **treatment** trials (~~treatment and cancer control~~)-deemed appropriate...

Section 9.0

Page 11

Descriptive Factors

The following text has been added to Section 9.4, as this is now categorical:

9.5 Tumor stage: **I vs. II vs. III vs. IV**

The following text was removed because this information is collected upon registration:

~~9.6 Treatment location.~~

The following text was removed because this study is only open to treatment trials and the reference to “cancer control” was inadvertently left in the protocol: The remainder of this section has been renumbered.

~~9.8 Trial type: Treatment vs. cancer control~~

Section 10.0

Page 12

Statistical Considerations

The following text has been removed in the first paragraph of Section 10.1 because this study is only open to treatment trials and the reference to “cancer control” was inadvertently left in the protocol.

Over 12,900 patients have been accrued in the past 3 years to 126 NCCTG clinical trials (~~both treatment and control~~) of which the Mayo Clinic...